Your browser doesn't support javascript.
loading
STAT3 protects HSCs from intrinsic interferon signaling and loss of long-term blood-forming activity.
Patel, Bhakti; Zhou, Yifan; Babcock, Rachel L; Ma, Feiyang; Zal, Malgorzata A; Kumar, Dhiraj; Medik, Yusra B; Kahn, Laura M; Pineda, Josué E; Park, Elizabeth M; Tang, Ximing; Raso, Maria Gabriela; Zal, Tomasz; Clise-Dwyer, Karen; Giancotti, Filippo G; Colla, Simona; Watowich, Stephanie S.
Affiliation
  • Patel B; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhou Y; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Babcock RL; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ma F; MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
  • Zal MA; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA, USA.
  • Kumar D; Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA.
  • Medik YB; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kahn LM; Herbert Irving Cancer Center and Department of Genetics and Development, Columbia University, New York, NY, USA.
  • Pineda JE; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Park EM; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Tang X; MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
  • Raso MG; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zal T; MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
  • Clise-Dwyer K; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Giancotti FG; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Colla S; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Watowich SS; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
bioRxiv ; 2023 Feb 11.
Article in En | MEDLINE | ID: mdl-36798265
ABSTRACT
STAT3 function in hematopoietic stem and progenitor cells (HSPCs) has been difficult to discern as Stat3 deficiency in the hematopoietic system induces systemic inflammation, which can impact HSPC activity. To address this, we established mixed bone marrow (BM) chimeric mice with CreER-mediated Stat3 deletion in 20% of the hematopoietic compartment. Stat3-deficient HSPCs had impaired hematopoietic activity and failed to undergo expansion in BM in contrast to Stat3-sufficient (CreER) controls. Single-cell RNA sequencing of Lin-ckit+Sca1+ BM cells revealed altered transcriptional responses in Stat3-deficient hematopoietic stem cells (HSCs) and multipotent progenitors, including intrinsic activation of cell cycle, stress response, and interferon signaling pathways. Consistent with their deregulation, Stat3-deficient Lin-ckit+Sca1+ cells accumulated γH2AX over time. Following secondary BM transplantation, Stat3-deficient HSPCs failed to reconstitute peripheral blood effectively, indicating a severe functional defect in the HSC compartment. Our results reveal essential roles for STAT3 in HSCs and suggest the potential for using targeted synthetic lethal approaches with STAT3 inhibition to remove defective or diseased HSPCs.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: BioRxiv Year: 2023 Document type: Article Affiliation country: Estados Unidos

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: BioRxiv Year: 2023 Document type: Article Affiliation country: Estados Unidos